A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2030

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

SHR-A1811

DRUG

Pyrotinib

Trial Locations (1)

RECRUITING

Shengjing Hospital affiliated to China Medical University, Shenyang

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Shengjing Hospital

OTHER